51 Republican senators push FDA to reconsider generic abortion pill's approval
51 Republican senators are storming the gates of bureaucracy, demanding the FDA rethink its latest nod to a generic abortion pill.
In a bold move, these lawmakers, led by Sen. Lindsey Graham of South Carolina, penned a letter to Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary, pressing for a reversal of the recent approval of a generic version of mifepristone, a key drug in medication abortions, as Breitbart reports.
Last week, before the senators fired off their letter on Thursday, the FDA gave the green light to this generic form of mifepristone, produced by Evita Solutions LLC, a company openly championing abortion access.
The agency declared the drug equivalent to the brand-name Mifeprex by Danco Laboratories, meeting all approval standards.
Yet, this decision landed while a safety review of mifepristone -- ordered by the Department of Health and Human Services -- is still underway, raising eyebrows over timing and priorities.
Safety concerns take center stage
Here’s the rub: the ongoing safety review stems from studies hinting at complication rates far higher than the FDA previously admitted. The senators are waving a red flag, arguing that approving a generic version now is like handing out parachutes mid-crash investigation.
Adding fuel to the fire, the lawmakers pointed out that the Biden administration previously stripped away key safeguards on Mifepristone, such as in-person dispensing rules. They’re urging the FDA to reinstate those protections and slam the brakes on further generic approvals until the safety review wraps up.
They also aimed current FDA guidance allowing pharmacies to mail-order these drugs with little oversight. The senators want that policy scrapped, arguing it’s a free-for-all that sidesteps medical consultation.
And frankly, when drugs this serious are shipped like Amazon packages, it’s hard not to see their point.
State laws under siege
“Unrestricted access to abortion pills is systematically undermining states’ rights and violating pro-life state laws,” the senators wrote in their letter. That’s a sharp jab at a system they believe lets abortion drugs flow into states with tight restrictions, post-Dobbs, eroding local efforts to protect life.
Consider the numbers: according to the Guttmacher Institute, medication abortions made up 63% of all abortions in the U.S. healthcare system in 2023, a jump from 53% in 2020 and just 39% in 2017. That’s roughly 642,700 unborn lives, a staggering figure that doesn’t even count pills slipped through underground networks.
Those stats paint a grim picture for pro-life advocates who see state-level protections crumbling under a flood of mail-order meds. The senators are sounding an alarm, and it’s not just rhetoric—it’s a call to action against what they view as federal overreach.
How medication abortions work
Let’s break down what mifepristone does, since it’s at the heart of this debate. The drug blocks progesterone, a vital hormone for pregnancy, causing the uterine lining to break down and cutting off nourishment to the developing baby, who then dies.
The second drug in the regimen, misoprostol, triggers contractions and bleeding to expel the baby from the uterus. It’s a two-step process that’s become the go-to method for most abortions in the formal healthcare system today.
Evita Solutions LLC, the maker of this new generic, isn’t shy about its mission to “normalize abortion” and make it widely accessible. While some may cheer that goal, others -- especially these 51 senators -- see it as a direct challenge to the sanctity of life and state authority.
A plea for the unborn
“Under your leadership, we have seen a strong commitment to reevaluating the policies that affect the most vulnerable among us -- the unborn,” the senators noted in their letter. It’s a nod to Kennedy and Makary, but also a polite nudge: don’t stop now when the stakes are this high.
The senators aren’t just asking for a pause -- they want generic versions included in the safety review and a full rollback of loosened regulations.
Their argument is clear: if the science isn’t settled, why rush more drugs into circulation? In a culture already wrestling with deep divisions on life issues, this push for caution might just resonate with those tired of progressive policies steamrolling over moral concerns.





